Episode

11AM Hour: Kalshi CEO on Prediction Markets, Former Defense Secretary Mark Esper & Revolution Medicines CEO on Pancreatic Cancer Drug Breakthrough 6/1/26

Podcast: Squawk on the Street
Published: Jun 1, 2026
Duration seconds: 2615
Processing state: not_requested
Canonical source: https://www.cnbc.com
Audio: https://dts.podtrac.com/redirect.mp3/cnbc.simplecastaudio.com/772daf2b-4aa5-445b-9969-6ecd181231b1/episodes/fce7f229-b60c-4bbf-9c9d-865c0215c724/audio/128/default.mp3?aid=rss_feed&awCollectionId=772daf2b-4aa5-445b-9969-6ecd181231b1&awEpisodeId=fce7f229-b60c-4bbf-9c9d-865c0215c724&feed=GcylmXl7
JSON: /v1/public/podcasts/squawk-on-the-street-731896/episodes/11am-hour-kalshi-ceo-on-prediction-markets-former-defense-secretary-mark-esper-revolution-medicines-ceo-on-pancreatic-cancer-drug-breakthrough-6-1-26
Markdown: /podcast/squawk-on-the-street-731896/11am-hour-kalshi-ceo-on-prediction-markets-former-defense-secretary-mark-esper-revolution-medicines-ceo-on-pancreatic-cancer-drug-breakthrough-6-1-26.md

Actions

POST https://stenobird.com/v1/public/podcasts/squawk-on-the-street-731896/episodes/11am-hour-kalshi-ceo-on-prediction-markets-former-defense-secretary-mark-esper-revolution-medicines-ceo-on-pancreatic-cancer-drug-breakthrough-6-1-26/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/squawk-on-the-street-731896/11am-hour-kalshi-ceo-on-prediction-markets-former-defense-secretary-mark-esper-revolution-medicines-ceo-on-pancreatic-cancer-drug-breakthrough-6-1-26.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

The CEO of Kalshi joins to discuss the company's latest product announcements and the regulatory environment for prediction markets. Then, Former Defense Secretary Mark Esper helps break down the latest headlines on the war with Iran. We also speak with the CEO of D-Wave Quantum following the U.S. government's recent investment in quantum companies. Plus, the CEO of Revolution Medicines joins to discuss the company's pancreatic cancer drug that nearly doubled survival rates. Squawk on the Street Disclaimer